Antares sales and marketing update

Antares launched Otrexup in the U.S. to deliver subcutaneous methotrexate to treat adults with rheumatoid arthritis or psoriasis and children with polyarticular juvenile idiopathic arthritis (pJIA). Specifically, the self-injectable formulation of methotrexate delivered using Antares' Vibex autoinjector technology is indicated in adults with severe active RA who have an inadequate response or intolerance to first-line therapy or with severe recalcitrant, disabling psoriasis who have an inadequate response to other therapies. The wholesale acquisition cost is $548 for four weekly subcutaneous injections of 10, 15, 20 or 25 mg methotrexate. ...